Vaccines Getting Personal with Neoantigen-Based Therapeutic Cancer

Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells. Cancer Immunol Res; 1(1); 11–15. 2013 AACR.

[1]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[2]  P. van Endert,et al.  Peptidases trimming MHC class I ligands. , 2013, Current opinion in immunology.

[3]  N. Hacohen,et al.  Systematic Identification of Personal Mutated Tumor-Specific Neoantigens in CLL , 2012 .

[4]  D. DeLuca,et al.  Mutated Bcr-abl Generates Immunogenic T Cell Epitopes in Cml Patients Nih Public Access Author Manuscript , 2022 .

[5]  K. Döhner,et al.  Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. , 2012, Blood.

[6]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[7]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[8]  B. Walker,et al.  Aminopeptidase Substrate Preference Affects HIV Epitope Presentation and Predicts Immune Escape Patterns in HIV-Infected Individuals , 2012, The Journal of Immunology.

[9]  Steven A. Rosenberg,et al.  Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.

[10]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[11]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[12]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[13]  Catherine J. Wu,et al.  Applications of next-generation sequencing to blood and marrow transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Morten Nielsen,et al.  Prediction of epitopes using neural network based methods. , 2011, Journal of immunological methods.

[15]  Harris Papadopoulos,et al.  Machine learning competition in immunology - Prediction of HLA class I binding peptides. , 2011, Journal of immunological methods.

[16]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[18]  S. H. van der Burg,et al.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.

[19]  S. Neelapu,et al.  Vaccination strategies in follicular lymphoma , 2009, Current hematologic malignancy reports.

[20]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[21]  C. Melief,et al.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.

[22]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[23]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[24]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[25]  A. Anichini,et al.  Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy , 2006, Clinical Cancer Research.

[26]  C. Huber,et al.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Rosenberg,et al.  T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product , 2004, The Journal of Immunology.

[28]  J. Nesland,et al.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Espinosa,et al.  Point Mutation in Essential Genes with Loss or Mutation of the Second Allele , 2001, The Journal of experimental medicine.

[30]  Yan P. Yuan,et al.  Frameshift peptide‐derived T‐cell epitopes: A source of novel tumor‐specific antigens , 2001, International journal of cancer.

[31]  P. Coulie,et al.  A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. , 2001, Cancer research.

[32]  E. Schaftingen,et al.  High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. , 2001, Cancer research.

[33]  M. Vikkula,et al.  New Helicase Gene Antigen Generated by a Point Mutation in a Anti-Melanoma CTL Directed Against an High Frequency of Autologous , 2000 .

[34]  T. Hercend,et al.  A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation , 1999, European journal of immunology.

[35]  M. Eisenstein,et al.  CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma , 1997, Nature.

[36]  J. Shabanowitz,et al.  The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68 , 1997, The Journal of experimental medicine.

[37]  Michael Feldman,et al.  Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides , 1995, Nature Medicine.

[38]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.